AssayIndex
Tissue-repair and immunomodulatory peptides

BPC-157

Body Protection Compound 157 · PL 14736 · bepecin · C62H98N16O22 · monoisotopic 1418.7093 Da. The index holds 591 assay reports on this compound across 94 batches from 19 suppliers.

591 reports94 batchesmedian 99.15 %index spec 98.0 %
Section 1

Analytical fingerprint

Hand-authored chemistry. These properties describe the substance and do not change when a record is added.

BPC-157 is the index's second-highest-volume compound and its easiest high-volume assay. Fifteen residues, no oxidisable side chains, and a clean early elution at 9.6 min mean inter-lab agreement is excellent (limits of agreement ±0.22 pp) and the purity distribution is tight and high — index median 98.9 %, IQR 0.6 pp. Two consequences. First, a BPC-157 report below 97 % is a genuine outlier and usually reflects an incomplete final coupling, visible as the −57 Da des-Gly species. Second, because purity is uninformative at the top of the range, the discriminating measurements for BPC-157 are peptide content and water: the spread in mg-per-vial recovery across suppliers is far wider than the spread in purity, and the supplier scorecards weight it accordingly.

Molecular formula
C62H98N16O22
Monoisotopic mass
1418.7093Da
Average mass
1419.53Da
Residues
15
Nominal retention (RG-2, 30 min)
9.62min
Retention window
0.25min
Counter-ion as usually shipped
acetate
Typical label claims
2 mg · 5 mg · 10 mg
Analytical difficulty (index scale)
0.90 — straightforward
Purity is a defined quantity
YES
Section 2

Representative chromatogram

Drawn from this page's own medians. Not a scan, not an illustration, and not any single report.

027835566835011133 BPC-1579.62 min · 99.15 % 9.28 same trace · ×200 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 05101520253035 Retention time (min) Response (mAU)
Figure 1. A representative BPC-157 trace on the index reference method RG-2, constructed from this page's own numbers: the main peak carries the index median purity of 99.15 % area at the nominal retention time of 9.62 min, and each impurity peak carries the median area the index has observed for that named species at its characteristic retention offset. It is not a scan of any single report — every individual record's own chromatogram is on its own page. The lower panel is the same trace at a stated vertical expansion, baseline-corrected, so the impurities are visible; the main peak runs off-scale there by design. Baseline noise is seeded from the compound slug.
Section 3

What the index has observed

Arithmetic over the 591 records the index holds. Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.

Median purity 99.15% n=591
Interquartile range 1.12pp n=591
Minimum 96.99% n=591
Maximum 99.93% n=591
Pass rate vs spec 93.4% n=591
Median recovery vs claim 98.4% n=361
Median water 4.68% n=591
Median |mass error| 2.4ppm n=502
0397811792.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=197.00–97.25 %: n=197.25–97.50 %: n=597.50–97.75 %: n=1197.75–98.00 %: n=2198.00–98.25 %: n=4098.25–98.50 %: n=5398.50–98.75 %: n=5898.75–99.00 %: n=7599.00–99.25 %: n=5599.25–99.50 %: n=6599.50–99.75 %: n=6799.75–100.00 %: n=139median 99.15 Purity (% area) Reports
Figure 2. Purity distribution across all 591 BPC-157 records. Dashed line is this compound's median (99.15 %); the solid vertical is the index acceptance specification for the tissue-repair and immunomodulatory peptides class (98.0 %). Domain is fixed at 92–100 % on every purity histogram on this site so that compounds can be compared by eye — a wide distribution here is a hard compound, a narrow one is an easy one, and neither is a statement about the suppliers.
Section 4

By supplier

Suppliers with fewer than two purity records on this compound are omitted from the figure rather than drawn as a line. The full table, including the thin cells, is on the by-supplier page.

96.897.397.998.599.099.6100.2WXTWXT: Q1 98.09, median 98.37, Q3 99.07, n=72n=72GGPepsGGPeps: Q1 98.80, median 99.06, Q3 99.53, n=71n=71JEEPJEEP: Q1 99.07, median 99.41, Q3 99.80, n=43n=43QYBQYB: Q1 99.81, median 99.93, Q3 99.93, n=35outlier 99.48outlier 99.53outlier 99.55outlier 99.56outlier 99.61n=35QSCQSC: Q1 99.36, median 99.91, Q3 99.93, n=34n=34KPKP: Q1 98.28, median 98.51, Q3 98.83, n=34n=34ERPERP: Q1 98.88, median 99.21, Q3 99.63, n=33n=33CPCCPC: Q1 97.93, median 98.48, Q3 98.70, n=30n=30MKMMKM: Q1 98.81, median 98.97, Q3 99.34, n=28n=28WWBWWB: Q1 99.45, median 99.80, Q3 99.93, n=26n=26TFCTFC: Q1 98.78, median 99.19, Q3 99.66, n=25n=25HomopeptideHomopeptide: Q1 99.26, median 99.39, Q3 99.71, n=25n=25BCHBCH: Q1 97.90, median 98.21, Q3 98.44, n=23n=23FGPFGP: Q1 99.49, median 99.75, Q3 99.93, n=22n=22SWBSWB: Q1 98.73, median 99.36, Q3 99.71, n=21n=21HJHJ: Q1 99.20, median 99.71, Q3 99.93, n=21n=21SGNSGN: Q1 98.31, median 98.55, Q3 98.90, n=17n=17GL BiochemGL Biochem: Q1 98.39, median 98.55, Q3 99.03, n=16n=16SSASSA: Q1 98.32, median 98.90, Q3 99.41, n=15n=15 Purity (% area)
Figure 3. BPC-157 purity by supplier, ordered by coverage. The vertical line is the index acceptance specification. Boxes that overlap are suppliers this dataset cannot separate, and most of them overlap.

Full per-supplier table with n= caveats →

Section 5

Characteristic impurities and degradants

The left three columns are authored chemistry — what this molecule characteristically carries and where it elutes. The right three are what the index has actually reported.

Named speciesΔRT (min, RG-2)Δ mass (Da)Seen inMedian % areaMax % area
des-Gly truncate (−57 Da)-0.34-57.02184%0.131.32
[D-Val]-diastereomer-0.14mass-identical80%0.101.62
pyroglutamate cyclisation (−17 Da)+0.31-17.02779%0.091.39
acetylated N-terminus (+42 Da)+0.48+42.01178%0.091.56
truncated (1-12)-0.96-285.13272%0.051.53
BPC-157 arginine-salt artefact-0.55mass-identical66%0.041.52

Degradation pathways

  • N-terminal pyroglutamate formation on storage of the free-base form
  • Asp-Gly aspartimide during synthesis
  • oxidative degradation is negligible — no Met, no Cys, no Trp

Full impurity profile, with what each named species implies about the synthesis →

Section 6

Clinical context

Included because it is routinely misapplied. Trial data describes a licensed medicinal product manufactured under a marketing authorisation, and it does not transfer to research-grade material of unknown provenance.

BPC-157 has no completed human efficacy trial in any indication; the published literature is overwhelmingly rodent. It was added to WADA's prohibited list in 2022. The index makes no claim about effect.

Section 7

Quarterly coverage

QuarterReportsMedian purityRange
2024-Q12n<397.98–98.29
2024-Q21899.4198.70–99.93
2024-Q34699.0497.77–99.93
2024-Q42898.9598.00–99.93
2025-Q16499.4197.91–99.93
2025-Q24999.1998.08–99.93
2025-Q37199.3597.90–99.93
2025-Q47898.9197.81–99.93
2026-Q18598.9596.99–99.93
2026-Q212598.8997.11–99.93
2026-Q32599.2297.27–99.93

Quarter-by-quarter detail →

Section 8

Most recent records

The 25 most recent BPC-157 records of 591.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-041387WWBWWB-2606-H3906Janoshik2026-Q398.954.64—Laboratory-retained1MARGINAL
AX-2026-043365CPCCPC-2602-W2646Medutest2026-Q398.562.80—Supplier-supplied1MARGINAL
AX-2026-041385WWBWWB-2606-H3906Medutest2026-Q399.314.31—Supplier-supplied1MARGINAL
AX-2026-043503BCHBCH-2603-G6422Janoshik2026-Q398.464.32—Supplier-supplied1MARGINAL
AX-2026-041390WWBWWB-2606-H3906Medutest2026-Q399.474.8499.3Supplier-supplied1MARGINAL
AX-2026-041386WWBWWB-2606-H3906VendorInvestigate2026-Q399.324.8899.2Buyer-sourced1MARGINAL
AX-2026-041380WWBWWB-2606-H3906PeptideMeter2026-Q399.454.52—Supplier-supplied1MARGINAL
AX-2026-041383WWBWWB-2606-H3906PeptideMeter2026-Q399.174.8491.2Supplier-supplied1MARGINAL
AX-2026-042499SWBSWB-2607-Y5787Kestrel2026-Q399.934.2594.4Supplier-supplied0PASS
AX-2026-041388WWBWWB-2606-H3906Janoshik2026-Q399.594.24105.8Supplier-supplied1MARGINAL
AX-2026-043504BCHBCH-2603-G6422Janoshik2026-Q398.384.4595.5Supplier-supplied1MARGINAL
AX-2026-043502BCHBCH-2603-G6422PeptideMeter2026-Q397.724.86—Buyer-sourced1FAIL
AX-2026-041378WWBWWB-2606-H3906Janoshik2026-Q399.224.6199.2Supplier-supplied1MARGINAL
AX-2026-043501BCHBCH-2603-G6422PeptideMeter2026-Q398.374.75100.8Supplier-supplied1MARGINAL
AX-2026-043500BCHBCH-2603-G6422VendorInvestigate2026-Q397.864.82—Buyer-sourced1FAIL
AX-2026-041379WWBWWB-2606-H3906Janoshik2026-Q399.724.5195.4Supplier-supplied1MARGINAL
AX-2026-041389WWBWWB-2606-H3906PeptideMeter2026-Q399.584.69—Supplier-supplied1MARGINAL
AX-2026-043544BCHBCH-2603-L7546Medutest2026-Q398.215.21—Supplier-supplied1MARGINAL
AX-2026-041377WWBWWB-2606-H3906Janoshik2026-Q399.934.4995.4Supplier-supplied0PASS
AX-2026-043363CPCCPC-2602-W2646VendorInvestigate2026-Q398.522.9790.1Buyer-sourced1MARGINAL
AX-2026-041381WWBWWB-2606-H3906Janoshik2026-Q399.364.2990.3Laboratory-retained1MARGINAL
AX-2026-043543BCHBCH-2603-L7546PeptideMeter2026-Q397.275.5891.9Supplier-supplied1FAIL
AX-2026-043364CPCCPC-2602-W2646PeptideMeter2026-Q397.642.89—Buyer-sourced1FAIL
AX-2026-042344HJHJ-2511-U3414Janoshik2026-Q299.184.92—Supplier-supplied2MARGINAL
AX-2026-041384WWBWWB-2606-H3906PeptideMeter2026-Q399.504.5297.9Supplier-supplied1MARGINAL